Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...